5种靶向抗肿瘤药物不良反应的调查与分析  

Survey and Analysis of Adverse Reactions of Five Target-Based Antineoplastic Drugs

作　　者：储悄悄 刘韬[1] 熊慧瑜[2] 魏雪[1] 黄红兵[1] 潘莹[1] 

机构地区：[1]华南肿瘤学国家重点实验室,中山大学肿瘤防治中心,广东广州510060 [2]广东省药品不良反应监测中心,广东广州510080

出　　处：《今日药学》2014年第9期675-678,共4页Pharmacy Today

基　　金：广东省医院药学研究基金(编号:2012G28);广东省自然科学基金课题(编号:10451008901004256);广东省科技计划项目(编号:2012B020306001)

摘　　要：目的调查本院常用的5种靶向抗肿瘤药物的不良反应发生情况。方法收集整理本院2011-01-2012-06使用过利妥昔单抗、曲妥珠单抗、贝伐珠单抗、厄洛替尼、卡培他滨5种药物所有病例,对用药期间死亡病例进行用药相关分析;同时随机抽取其中94份病历进行用药不良反应分析,抽查结果与本院实际不良反应上报结果进行交叉对比。结果 5种药物在本院不良反应上报率分别为1.4%、0.0%、0.0%、0.0%、0.2%,仅利妥昔单抗上报3例严重不良反应;抽样调查的不良反应率分别为6.7%、17.6%、30.0%、26.1%、26.3%,均为一般不良反应;3例患者用药期间死亡,但与用药无关。结论 5种靶向抗肿瘤药物相对安全,未发现药物导致死亡情况,但存在一般不良反应,上报率低于发生率,因此靶向抗肿瘤药物不良反应监测和报告工作仍需加强。Objective To analyze the drug-related adverse reaction of the 5 target-based antineoplastic drugs which were used in the hospital. Methods The data of all inpatients who used rituximab,trastuzumab,bevacizumab,erlotinib and capecitabine in the hospital from January 2011 to June 2012 were collocated. Patients who dead during the course of medication were analyzed. 94 medical records were drew at random,and the adverse drug reaction was analyzed. Then the result of sample investigation and the result of reports of adverse drug reaction in our hospital were cross contrasted.Results The adverse reaction report rate of the 5 drugs was 1. 4%,0. 0%,0. 0%,0. 0%,and 0. 2%,respectively.Only rituximab was reported 3 serious cases of adverse reaction. The adverse reaction rate in the sample investigation was6. 7%,17. 6%,30. 0%,26. 1%,and 26. 3% respectively,all of which belong to ordinary cases. Though 3 patients died during the course of medication,but it had nothing to do with the drugs being used. Conclusion These 5 drugs are relative safe,as has no deaths caused by these drugs,but ordinary cases of adverse reactions exist. The reported rate is lower than the incidence rate,so monitoring and reporting antineoplastic adverse drug reaction still needs strengthening.

关 键 词：靶向治疗 利妥昔单抗 曲妥珠单抗 贝伐珠单抗 厄洛替尼 卡培他滨 药物不良反应 

分 类 号：R97[医药卫生—药品]